Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Atogepant Shows Efficacy for Migraine Prevention

Publish date:: September 17, 2019

Key clinical point: Atogepant showed safety and efficacy for migraine headache prevention in a phase 2/3 study.

Major finding: Migraine headache frequency fell by an average 3.55-4.23 days per month, compared with an average drop of 2.85 days with placebo.

Study details: A multicenter, phase 2/3 dose-ranging study with 834 U.S. patients.

Disclosures: The study was sponsored by Allergan, the company developing atogepant and ubrogepant. Dr. Dodick has been a consultant to Allergan and to several other drug companies.

Citation:

REPORTING FROM AHS 2019

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Headache & Migraine

HIT-6 may help track meaningful change in chronic migraine,

Choroid plexuses may play a role in migraine,

Multiple traits more common in difficult-to-treat patients with migraine,

Marijuana for migraine? Some tentative evidence,

Low vitamin D levels in patients with migraine,